A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 3, 1999, Pages 259-265

  Aebi, S ^a   Schnider, T W ^a   Los, G ^b   Heath, D D ^b   Darrah, D ^b   Kirmani, S ^b   McClay, E F ^b   D'Agostino, H ^b   Plaxe, S C ^b   Fink, D ^b   De Las Alas, M M ^b   Howell, S B ^b   Christen, R D ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

NONMEM; Paclitaxel; Progesterone

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PROGESTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CROSSOVER PROCEDURE; DISEASE COURSE; FEMALE; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MALE; P-GLYCOPROTEIN; PACLITAXEL; PROGESTERONE;

EID: 0032814243     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050976     Document Type: Article

References (29)

1. 1. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835-842
2. 2. Reference deleted
3. 3. Berg SL, Tolcher A, O'Shaughnessy JA, Denicoff AM, Noone M, Ognibene FB, Cowan KH, Balis FM (1995) Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 13: 2039-2042
4. 4. Boeckmann AJ, Sheiner LB, Beal SL (1994) NONMEM user's guide - Part V. Introductory guide. University of California, San Francisco
5. 5. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610-618
6. 6. Christen RD, McClay EF, Plaxe SC, Yen SSC, Kim S, Kirmani S, Wilgus LL, Heath DD, Shalinsky DR, Freddo JL, Braly PS, O'Quigley J, Howells SB (1993) Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. J Clin Oncol 11: 2417-2426
7. 7. Fardel O, Lecureur V, Guillouzo A (1996) The P-glycoprotein multidrug transporter. Gen Pharmacol 27: 1283-1291
8. 8. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonnadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationship in humans. J Clin Oncol 13: 180-190
9. 9. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP (1993) Taxol: mechanisms of action and resistance. Monogr Natl Cancer Inst: 55-61
10. 10. Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135
11. 11. Ichikawa-Haraguchi M, Sumizawa T, Yoshimura A, Furukawa T, Hiramoto S, Sugita M, Akiyama S (1993) Progesterone and its metabolites: the potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland. Biochim Biophys Acta 1158: 201-208
12. 12. Kavallaris M, Kuo DYS, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293
13. 13. Licht T, Pastan I, Gottesman M, Herrmann F (1994) P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol 69: 159-171
14. 14. Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS, Colvin M (1987) High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71: 53-59
15. 15. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635-1642
16. 16. Malfetano J, Beecham JB, Bundy BN, Hatch KD (1993) A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers. A Gynecologic Oncology Group study. Am J Clin Oncol 16: 149-151
17. 17. Minotti AM, Barlow SB, Cabral F (1991) Resistance to antimitotic drugs in Chinese hamster ovray cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266: 3987-3994
18. 18. Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O'Brien JP (1995) Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13: 1958-1965
19. 19. Murren JR, DeVita Jr. VT (1995) Another look at multidrug resistance. PPO Updates 9: 1-12
20. 20. Pastan I, Gottesman M (1987) Multiple-drug resistance in human cancer. N Engl J Med 316: 1388-1393
21. 21. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications. Williams and Wilkins, Baltimore
22. 22. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H, Lambert HE (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14: 1545-1551
23. 23. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40 [Suppl]: S13-19
24. 24. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV (1994) Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12: 532-538
25. 25. Sonnichsen DS, Rolling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27: 256-269
26. 26. Van Acker KL, De Greef C, Eggermont J, Zhang P, Vandenberghe P, Boogaerts MA (1995) Detection of P-glycoprotein with a rapid flow cytometric functional assay using Fluo-3: evaluation of sensitivity, specificity and feasibility in multiparametric analysis. Leukemia 9: 1398-1406
27. 27. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL (1998) Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16: 1811-1819
28. 28. Waud WR, Gilbert KS, Harrison SD Jr., Griswold DP Jr. (1992) Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo. Cancer Chemother Pharmacol 31: 255-257
29. 29. Yang CP, DePinho SG, Greenberger LM, Arceci RJ, Horwitz SB (1989) Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 264: 782-788